Moores Cancer Center Accelerates Clinical Trial Activation, Improving Patient Access to Novel Therapies
核心洞察
Moores Cancer Center (搜索) implemented the EY Clinical Trial Fast Lane (搜索) solution to expedite the activation of high-priority clinical trials.
The new process significantly reduced clinical trial activation times, providing patients with access to innovative treatments up to 11 times faster.
The initiative also led to broader process improvements across all clinical trials at the center, enhancing overall efficiency.
Moores Cancer Center (搜索) at UC San Diego Health has dramatically accelerated the activation of its highest priority clinical trials through the implementation of the EY Clinical Trial Fast Lane (搜索) solution. This initiative has significantly reduced the time required to bring novel cancer (搜索) therapies to patients, offering access to innovative, investigational treatments up to 11 times faster than traditional timelines.
The EY Clinical Trial Fast Lane (搜索) solution is designed to streamline the activation process, achieving activation in 45 to 60 working days. This is accomplished through rapid performance of functional services, process excellence, a deep understanding of clinical trial operations, real-time transparency across all involved stakeholders, and prompt risk mitigation. The accelerated timelines mean that patients have quicker access to potentially life-saving treatments.
Beyond the immediate benefits of faster activation for priority trials, Moores Cancer Center (搜索) has also implemented related process improvements to enhance clinical trial activation timelines across all clinical trials. This comprehensive approach ensures that a greater number of patients can benefit from cutting-edge research and therapeutic advancements.
By optimizing the clinical trial activation process, Moores Cancer Center (搜索) is not only improving patient access to novel therapies but also setting a new standard for efficiency and responsiveness in cancer (搜索) research. This advancement underscores the importance of innovative solutions in overcoming traditional barriers to clinical trial participation, ultimately benefiting patients and advancing the field of oncology.